About GRO Biosciences
GRO Biosciences is a Healthcare company based in Boston (United States) founded in 2016. Synthetic biology tools are developed via genetic code recoding techniques. GRO Biosciences has raised $91.15 million across 6 funding rounds from investors including Bayer, Atlas Venture and Redmile Group. The company has 22 employees. Its chief executive, as recorded, is Daniel Mandell. GRO Biosciences offers products and services including GRO Platform, ProGly Programs, and Biofoundry. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is GRO BIOSCIENCES INC. Its competitors include Insitro, Certara and HotSpot Therapeutics; 2 of its 3 listed competitors have raised funding.
Company details
GRO Biosciences was founded in 2016 and is based in Boston, United States. Operations focus on the synthetic biology sector, where computational biology is integrated with genetic recoding to reprogram organisms and biomaterials. This approach is used to simplify biological systems and improve their performance. Tools and methods are provided for applications in biomaterial engineering and organism modification.
- Headquarters Boston, United States
- Employees 22
- SectorsHealthcare
- Phone•••• ••••
- Website grobio.com
- Social LinkedIn X Facebook Instagram
- Legal Name Gro Biosciences Inc
- Total Equity Funding$91.15M (USD)
in 6 rounds
- Latest Funding Round$60.3M (USD), Series B
Jul 2024
- InvestorsBayer
& 7 more
- Employee Count22
Products & Services of GRO Biosciences
GRO Biosciences offers a comprehensive portfolio of products and services, including GRO Platform, ProGly Programs, and Biofoundry.
Enables access to non-standard amino acids for improved protein therapeutics.
Focuses on reversing autoimmunity via pre-glycosylated amino acids.
Supports production of advanced protein chemistries.
Funding Insights of GRO Biosciences
GRO Biosciences has successfully raised a total of $91.15M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $60.3 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $91.15M
- Total Rounds 6
- Last Round Series B — $60.3M
- First Round $2.1M
(Sep 2017)
- Investors Count 8
All 6 funding rounds of GRO Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2024 | $60.3M | Series B | – | Atlas Venture, Access Industries | |
| Nov 2021 | $25M | Series A | – | Bayer, Redmile Group | |
| Sep 2020 | $1M | Grant | – | – | |
| Mar 2019 | $3.75M | Series A | – | – | – |
| Feb 2019 | $225,000 | Grant | – | – | |
| Sep 2017 | $2.1M | Seed | – | Digitalis Ventures |
8 investors in total: 8 institutional.
Investors in GRO Biosciences
GRO Biosciences has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Bayer, Atlas Venture and Redmile Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Digitalis Ventures is engaged in health-focused investments. | digitalisventures.com | New York, United States | ||
Early-stage technology investments are targeted by this venture capital firm. | innovationendeavors.com | Palo Alto, United States | ||
Investment and holding company controlled by Len Blavatnik | accessindustries.com | New York, United States | ||
Venture capital fund backed by the US Government | seedfund.nsf.gov | Alexandria, United States | ||
Life science solutions for healthcare and agriculture are delivered. | 1863 | bayer.com | Leverkusen, Germany | |
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States | |
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States |
Investor details for GRO Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GRO Biosciences
16 people are tracked at GRO Biosciences (4 in leadership, 11 in board & advisors, 1 in team); the tracked headcount is 22.
| Name | Role | Group |
|---|---|---|
Daniel Mandell | CEO | Leadership |
Daniel J. Mandell | Co-founder And CEO | Leadership |
Christopher Gregg | Chief Scientific Officer | Leadership |
Precillia Redmond | Chief People Officer | Leadership |
Tamar Howson | Commercialization Advisor | Board & advisors |
Geoff Smith | Director | Board & advisors |
Andrew Ellington | Co-Founder & Scientific Advisor | Board & advisors |
Nicole Paulk | Scientific Advisor | Board & advisors |
Rakhshita Dhar | Director | Board & advisors |
Debra Peattie | Commercialization Advisor | Board & advisors |
Bruce Beutel | Director | Board & advisors |
Niels Kaarsholm | Scientific Advisor | Board & advisors |
George Church | Co-Founder & Chair, Scientific Advisory Board | Board & advisors |
Arthur Hiller | Commercialization Advisor | Board & advisors |
Nick Olsen | Director | Board & advisors |
Karen Bui | Biotechnology Project Manager | Team |
Complete people profiles for GRO Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GRO Biosciences
3 dated milestones of GRO Biosciences across 8 years, from founding to its latest funding, stage changes and deals.
- Founded GRO Biosciences is founded.
- Funding First funding round of $2.1M.
- Funding Latest funding round, Series B, of $60.3M.
Competitors of GRO Biosciences
GRO Biosciences has 3 listed competitors in our database, 2 of them funded. They include Insitro, Certara and HotSpot Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| certara.com | 2008 | Princeton, United States | 827 | Provider of a platform for in silico drug discovery and consulting services | ||
| hotspotthera.com | 2017 | Boston, United States | $210M | 37 | Developer of a platform for protein function analysis |
Detailed competitors of GRO Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of GRO Biosciences
The website of GRO Biosciences (grobio.com) receives about 1.6K visits a month.
- Monthly visits1.6K
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as GRO Biosciences (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gro Biosciences
Complete news archive for GRO Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GRO Biosciences
GRO Biosciences was founded in 2016 and raised its 1st funding round 1 year after it was founded.
GRO Biosciences is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Daniel Mandell is the CEO of GRO Biosciences, as recorded in our data.
GRO Biosciences is a funded company, having raised a total of $91.15M across 6 funding rounds to date. The company's 1st funding round was a Seed of $2.1M, raised on Sep 2017.
GRO Biosciences has 22 employees.
GRO Biosciences was founded in 2016 and is based in Boston, United States. Operations focus on the synthetic biology sector, where computational biology is integrated with genetic recoding to reprogram organisms and biomaterials. This approach is used to simplify biological systems and improve their performance. Tools and methods are provided for applications in biomaterial engineering and organism modification.
GRO Biosciences's top competitors include Insitro, HotSpot Therapeutics and Certara.
GRO Biosciences offers GRO Platform, ProGly Programs, and Biofoundry.
GRO Biosciences has 8 investors. Key investors include Bayer, Atlas Venture, Redmile Group, Digitalis Ventures, and Innovation Endeavors.
GRO Biosciences operates through Gro Biosciences Inc.